# Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

> **NCT03126786** · PHASE2 · COMPLETED · sponsor: **Clearside Biomedical, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** IVT aflibercept
- **DRUG:** Sham SC
- **DRUG:** SC CLS-TA

## Key facts

- **NCT ID:** NCT03126786
- **Lead sponsor:** Clearside Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-11
- **Primary completion:** 2018-04-17
- **Final completion:** 2018-04-17
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126786, "Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03126786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*